A detailed history of Vanguard Group Inc transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,261,195 shares of MORF stock, worth $75.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,261,195
Previous 2,321,046 2.58%
Holding current value
$75.8 Million
Previous $67 Million 18.74%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$26.64 - $40.31 $1.59 Million - $2.41 Million
-59,851 Reduced 2.58%
2,261,195 $79.6 Million
Q4 2023

Feb 14, 2024

BUY
$19.95 - $31.0 $4.26 Million - $6.62 Million
213,636 Added 10.14%
2,321,046 $67 Million
Q3 2023

Nov 14, 2023

BUY
$21.33 - $59.42 $4.28 Million - $11.9 Million
200,772 Added 10.53%
2,107,410 $48.3 Million
Q2 2023

Aug 14, 2023

BUY
$34.33 - $62.11 $7.41 Million - $13.4 Million
215,820 Added 12.76%
1,906,638 $109 Million
Q1 2023

May 15, 2023

BUY
$26.01 - $48.69 $531,696 - $995,320
20,442 Added 1.22%
1,690,818 $63.6 Million
Q4 2022

Feb 10, 2023

BUY
$24.14 - $30.37 $5.28 Million - $6.64 Million
218,669 Added 15.06%
1,670,376 $44.7 Million
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $2.78 Million - $4.17 Million
124,861 Added 9.41%
1,451,707 $41.1 Million
Q2 2022

Aug 12, 2022

BUY
$19.74 - $43.01 $1.75 Million - $3.8 Million
88,432 Added 7.14%
1,326,846 $28.8 Million
Q1 2022

May 13, 2022

BUY
$36.25 - $52.02 $1.49 Million - $2.14 Million
41,094 Added 3.43%
1,238,414 $49.7 Million
Q4 2021

Feb 14, 2022

BUY
$43.27 - $65.72 $445,205 - $676,193
10,289 Added 0.87%
1,197,320 $56.7 Million
Q3 2021

Nov 12, 2021

BUY
$53.61 - $67.5 $11.3 Million - $14.2 Million
210,472 Added 21.55%
1,187,031 $67.2 Million
Q2 2021

Aug 13, 2021

BUY
$45.13 - $64.99 $44.1 Million - $63.5 Million
976,559 New
976,559 $56 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.29B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.